Purchase this article with an account.
H. P. Sandoval, L. Fernández de Castro, D. Waterbury, K. Solomon; PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% at Trough Drug Effects in a Rabbit Model. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5677.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the ability of ketorolac 0.4% and bromfenac 0.09% to inhibit PGE2 at trough drug effect following cataract surgery in a rabbit model.
Twenty-nine New Zealand White rabbits of the same age and weight (7-9 lbs) were randomized to receive either ketorolac four-times daily (n=10) or bromfenac twice-daily (n=10) in the operative (right eye) commencing 1-day prior to cataract surgery. An additional 9 rabbits did not receive pre-operative dosing with an NSAID and served as controls. Post-operatively, the rabbits continued to receive ketrolac at four-times daily and bromfenac at 2-times daily dosing. On post-operative day 1, aqueous humor was obtained via a paracentesis from the operative eyes 4-6 hours following the last dose of ketorolac and 8-12 hours following the last dose of bromfenac. PGE2 levels were determined based on the aqueous samples using an ELISA immunoassay.
Ketorolac 0.4% inhibited PGE2 to a statistically greater extent than did bromfenac at trough drug effect. Mean PGE2 levels were 323.5 + 132.5 pg/mL with ketorolac and 507.8 + 185.5 pg/mL with bromfenac (P=.025). Both NSAIDs controlled PGE2 to a statistically significantly greater extent than did untreated control (mean of 6112.8 + 4879.6 pg/mL, P≤.003).
At trough drug levels, ketorolac inhibited PGE2 to a significantly greater extent than did bromfenac in a rabbit cataract surgery model.
This PDF is available to Subscribers Only